Sean Wallace has joined Darby Overseas Investments as senior managing director for Asia Pacific. He will be based in Hong Kong, and previously was head of Asia-Pacific capital markets for JP Morgan Chase. www.darbyoverseas.com
Capital Dynamics, a Switzerland-based private equity asset manager, has opened an office in Hong Kong. It will be run by CD director Markus Ableitinger
Colorado PERA has named Tim Moore as director of alternative investments. He joined PERA in 1996, and has worked on the alternatives staff since 1999. He replaces Chris Reilly, who left late last year. www.copera.org
OMERS has named Michael Nobrega as its new CEO, effective March 12. Nobrega is president and CEO of Borealis Infrastructure, which manages infrastructure investments for OMERS. www.omers.com
Astoria Generating Company Holdings LLC and EBG Holdings LLC have agreed to merge, in order to create a $5 billion power generation company serving the constrained energy markets in the New York and Boston metropolitan areas. The combined company will be named US Power Generating Company, with Astoria and EBG shareholders owning 46% and 54%, […]
Matthew Janchar has agreed to join Berkshire Partners as director of capital markets, where he will lead the firm's financing activities. He previously was a managing director with Oak Hill Advisors and, before that, worked in the leveraged finance group of Goldman Sachs. www.berkshirepartners.com
Alliance Semiconductor Corp. has completed the sale of its 79.31% stake in Solar Venture Partners for $5 million in cash to Willowridge and Thomas Weisel Partners. SVP portfolio companies include Crosslayer Networks, Epiance and Ontologent.
Sirtris Pharmaceuticals Inc., a Cambridge, Mass.-based developer of therapeutics that modulate an enzyme family called sirtuins, has filed for a $60 million IPO. It plans to trade on the Nasdaq under ticker symbol SIRT, with JPMorgan serving as lead underwriter. Sirtris has raised $67 million in VC funding since its 2002 inception (plus $15m in […]
Oncogenex Technologies Inc., a Vancouver-based drug company focused on cancer therapeutics, has amended its proposed IPO terms to five million common shares being offered at between $7.50 and $7.50 per share. It previously had been planning to offer 4.5 million shares being at between $10 and $12 per share. Oncogenex plans to trade on both […]
Helicos Biosciences Corp., a Cambridge, Mass.-based DNA sequencing company, has filed for a $100 million IPO. It plans to trade on the Nasdaq under ticker symbol HLCS, with UBS serving as lead underwriter. The company has raised around $67 million in VC funding from firms like Flagship Ventures, Atlas Venture, Highland Capital Partners, MPM Capital […]